Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
BioAge Labs said on Friday it is discontinuing the mid-stage trial of its experimental obesity drug after high levels of ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according ...
In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s ...
To receive the full newsletter in your inbox for free sign up here) An experimental immunotherapy drug is a potentially effective treatment for patients with bladder cancer who no longer respond to ...
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...
Eli Lilly plans a $3 billion expansion of its Wisconsin facility, creating 750 skilled jobs and boosting production capacity ...
Conversely, Eduardo Grunvald, MD, medical director of the weight management program at UC San Diego Health, sees less of an ...
The European Commission granted unconditional approval to Novo Holdings’ $16.5 billion takeover of Catalent, a decision both ...